Grünenthal Company Profile

15:07 EST 6th March 2015 | BioPortfolio

Grünenthal è una società farmaceutica indipendente, basata sulla ricerca con operazioni internazionali. E' sempre stata una società a capitale privato fin dalla sua fondazione nel 1946. I prodotti Grünenthal sono commercializzati in oltre 80 Paesi e il numero delle filiali è in continua crescita. Grünenthal occupa circa 4.800 persone a livello mondiale, persone che hanno dato un grande contributo per il successo della Società.L'ulteriore consolidamento attraverso una ricerca innovativa è una parte integrante della politica della nostra Società. L'ambizione di Grünenthal è quella di essere una società leader nella Ricerca e Sviluppo in campi selezionati: l'area dolore è la nostra competenza core.


Via Correggio, 43


Phone: 39-02-43051
Fax: 39-02-430555

News Articles [8 Associated News Articles listed on BioPortfolio]

Sascha Becker Will Join Grünenthal Group as new CFO

AACHEN, Germany, October 20, 2014 /PRNewswire/ -- Sascha Becker will be appointed to the Executive Board of the pharmaceutical company Grünenthal and take over the finance unit as Group Chief Fi...

Grünenthal terminates license agreement with Actavis for cebranopadol

Grünenthal, an independent, family-owned, international, research-based pharmaceutical company headquartered in Aachen, Germany, has terminated a license agreement with Actavis for the development a...

Grünenthal Group appoints Sascha Becker as group chief financial officer

German pharma company Grünenthal Group has appointed Sascha Becker as group chief financial officer, commencing in the first quarter of 2015.

EFIC-Grünenthal Grant: Supporting up-and-Coming Researchers in the Field of Pain

AACHEN, Germany and BRUSSELS, September 23, 2014 /PRNewswire/ -- Young scientists from any European member country of the European Pain Federation EFIC® are invited to apply for the EFIC-Gr...

Novartis pays $85m to shed Array, and other recent brush offs

Array BioPharma has joined an assortment of companies that have lost their big pharma partners in recent days. Array has been relinquished by Novartis, Dynavax discarded by GlaxoSmithKline, Grünentha...

"My Pain Feels Like…" Patient Initiative Gets the Status of European Best Practice

BRUSSELS, October 2, 2014 /PRNewswire/ -- The "My pain feels like…" initiative is presented today at an EU conference hosted by the European Economic and Social Committee under the patronage of...

Actavis and Grunenthal terminate Cebranopadol pact

Grunenthal announced the termination of the license agreement with Actavis for the development and commercialization of Cebranopadol, a novel analgesic for the treatment of chronic pain. Forest Labora...

New Haven Pharmaceuticals Expands Management Team With Two Senior-Level Appointments

BRANFORD, CT -- (Marketwired) -- 10/08/14 -- New Haven Pharmaceuticals, Inc. (the "Company" or "NHP"), a privately-held specialty pharmaceuticals company, has strengthened its management team with th...

Drugs and Medications [0 Results]


PubMed Articles [0 Results]


Clinical Trials [0 Results]


Companies [3 Associated Companies listed on BioPortfolio]


Grünenthal è una società farmaceutica indipendente, basata sulla ricerca con operazioni internazionali. E' sempre stata una società a capitale privato fin dalla sua fondazione nel 1946. I prodotti...


Grünenthal GmbH


More Information about "Grünenthal" on BioPortfolio

We have published hundreds of Grünenthal news stories on BioPortfolio along with dozens of Grünenthal Clinical Trials and PubMed Articles about Grünenthal for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Grünenthal Companies in our database. You can also find out about relevant Grünenthal Drugs and Medications on this site too.

Search BioPortfolio:

Corporate Database Quicklinks

Searches Linking to this Company Record